US7574681034 - ADR - After market: 0.988 0 (-0.11%)
NASDAQ:RDHL (8/10/2022, 7:09:17 PM)+0.06 (+6.3%)
|GICS Sector||Health Care|
|Earnings (Last)||06-23 2022-06-23/bmo||Earnings (Next)||08-25 2022-08-25/bmo|
|Ins Owners||N/A||Inst Owners||5.41%|
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
RedHill Biopharma Ltd. is a biopharmaceutical company focusing gastrointestinal and infectious diseases. The firm is focused on the commercialization in the United States (U.S.) of the GI-related products, Movantik (naloxegol),Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). A part form Company's pipeline consists of six therapeutic candidates RHB-204 dedicated to Nontuberculous mycobacterial (NTM) treatment, RHB-104 dedicated to Crohn's disease, RHB-102 antiemetic drug ondansetron, in development for multiple gastrointestinal indications, RHB-106 an oral capsule formulation for bowel preparation, Opaganib an inhibitor, administered orally, with anticancer, anti-inflammatory and anti-viral activities and RHB-107 inhibitor of serine proteases targeting multiple indications, including COVID-19, cancer, inflammatory lung diseases and gastrointestinal diseases.
REDHILL BIOPHARMA LTD-SP ADR
21 Ha'arba'a St.
TEL AVIV-YAFO 64739
CEO: Dror Ben-Asher
Talicia® - World Gastro 2022 congress (August 17-18): RedHill invited to give prestigious oral presentation of important data detailing high eradication rates...
It's time for the last breakdown of the biggest pre-market stock movers of the week and we look at what's happening Friday morning!
Targeting positive cash from operations to start during H2/22 Focus on earlier achievement of operational profitability thanks to a recently implemented...
/PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it will report...
Talicia's efficacy and safety profile evaluated in patients with H. pylori infection and diabetes mellitus, a large and challenging patient population...
Here you can normally see the latest stock twits on RDHL, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.